![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, November 30, 2022 9:51:39 PM
• Customer complaints for Recell are incredibly low.
• They have two indications (soft tissue repair & vitiligo) that are going in for a PMA supplement next month.
• Japan received their first stocking order for Recell in September and has already treated dozens of patients in that first month.
• Since Japan's healthcare industry is about a 1/3 the size of the U.S., it could be a 10 million dollar business in 3-4 years.
• Avita sees a big international potential of Recell being used in 20 countries, if not more. Plans in how to go about getting that done will happen in 2023.
• Their priority in 2023 is the launch for their soft tissue indication. Plans to file in December of this year. Expect approval in June 2023.
• The clinical outcome for their soft tissue repair study "was just exceptional". "We had a P-value of 025 that we had to meet or beat, and we beat it. And by beating it, that is really a healing definition."
• "Economically, the soft tissue repair market is 3-4 times bigger than the burn market. It sits in level 1 & 2 trauma centers. The synergy is rather interesting. Half of the burn centers are level 1 or 2 trauma centers. We will instantly get access to that broader indication on the day of approval and we have reimbursement. Secondly, in the level 1 and 2 trauma centers sits 25% of the burn market we don't call on." Their sales team will hit the ground running in those level 1 & 2 trauma centers that they didn't previously have access to.
• Avita will be doubling the size of their sales reps. Announcing those details in February.
• Vitiligo - They expect approval in June 2023. Estimated that it will get to market by January 2025.
• "What is most interesting to us is our most recent market research: 438,000 patient sought treatment for their vitiligo last year which is an enormous market because really none of those treatments are very effective. It happened in our trial that it was against a control and at 6 months where we had a responder group of about 80%, the control actually had a 0% responder to the standard of care today at 6 months. So, that is such a divergent outcome, we know that if we get it right, we will have a big winner...Well, ultimately this is a couple billion dollar market. You take those 438 (thousand) and you multiply them by $6,000, you get 2.5 billion."
Recent RCEL News
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/09/2024 02:40:53 PM
- AVITA Medical to Host Investor Webinar Briefing • GlobeNewswire Inc. • 08/08/2024 11:00:52 PM
- AVITA Medical Reports Second Quarter Financial Results • GlobeNewswire Inc. • 08/08/2024 08:04:00 PM
- AVITA Medical Names Robin VanDenburgh as SVP of U.S. Commercial Sales • GlobeNewswire Inc. • 08/01/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 08:11:11 PM
- AVITA Medical Expands Portfolio with Unique Dermal Matrix to Advance Wound Care • GlobeNewswire Inc. • 07/31/2024 08:05:00 PM
- AVITA Medical to Announce Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 07/11/2024 08:10:00 PM
- AVITA Medical Appoints Nicole Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary • GlobeNewswire Inc. • 07/01/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 12:48:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 11:36:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 08:39:30 PM
- AVITA Medical Achieves Milestone with First Case Using RECELL GO • GlobeNewswire Inc. • 06/05/2024 08:25:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 08:34:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/30/2024 08:28:05 PM
- AVITA Medical Announces FDA Approval of RECELL GO • GlobeNewswire Inc. • 05/30/2024 01:15:00 PM
- AVITA Medical to Host Investor Webinar Briefing • GlobeNewswire Inc. • 05/16/2024 10:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 08:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 08:02:24 PM
- AVITA Medical Reports First Quarter Financial Results • GlobeNewswire Inc. • 05/13/2024 08:01:00 PM
- AVITA Medical to Announce First Quarter 2024 Financial Results • GlobeNewswire Inc. • 04/15/2024 09:05:00 PM
- AVITA Medical Updates Expected First Quarter 2024 Revenue • GlobeNewswire Inc. • 04/10/2024 09:11:25 PM
- AVITA Medical Submits Response to FDA, Resuming Review Clock for RECELL GO PMA Supplement • GlobeNewswire Inc. • 02/29/2024 09:02:00 PM
- AVITA Medical to Present at TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/29/2024 02:00:00 PM
- AVITA Medical to Host Investor Webinar Briefing • GlobeNewswire Inc. • 02/23/2024 02:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 09:02:06 PM
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM
Swifty Global Reports Strong Q2 Performance and Prepares for Major Exchange Uplisting • DRCR • Aug 15, 2024 9:04 AM
Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM
POET Technologies Reports Second Quarter 2024 Financial Results • POET • Aug 15, 2024 8:04 AM